Compare CTM & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTM | SPRO |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 67.0M |
| IPO Year | 2022 | 2017 |
| Metric | CTM | SPRO |
|---|---|---|
| Price | $0.44 | $1.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | ★ 536.1K | 316.6K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 83.33 | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | $52,866,001.00 | ★ $66,802,000.00 |
| Revenue This Year | $4.94 | N/A |
| Revenue Next Year | $8.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 18.10 | ★ 39.24 |
| 52 Week Low | $0.34 | $0.96 |
| 52 Week High | $1.24 | $3.08 |
| Indicator | CTM | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 39.52 | 40.58 |
| Support Level | $0.34 | $0.96 |
| Resistance Level | $0.66 | $1.27 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 50.23 | 23.21 |
Castellum Inc is focused on building a successful technology services, solutions, and products company in the areas of cybersecurity, IT, electronic warfare, information warfare, system modernization, and information operations with businesses in the defense, federal, civilian, and commercial markets. Services include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and model-based systems engineering. The company maintains one operating and reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.